PL3424930T3 - Kryształ związku wykazującego aktywność hamującą JAK - Google Patents

Kryształ związku wykazującego aktywność hamującą JAK

Info

Publication number
PL3424930T3
PL3424930T3 PL17759943T PL17759943T PL3424930T3 PL 3424930 T3 PL3424930 T3 PL 3424930T3 PL 17759943 T PL17759943 T PL 17759943T PL 17759943 T PL17759943 T PL 17759943T PL 3424930 T3 PL3424930 T3 PL 3424930T3
Authority
PL
Poland
Prior art keywords
jak
crystal
compound
inhibiting activity
inhibiting
Prior art date
Application number
PL17759943T
Other languages
English (en)
Inventor
Fumi Higuchi
Original Assignee
Nippon Shinyaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co., Ltd. filed Critical Nippon Shinyaku Co., Ltd.
Publication of PL3424930T3 publication Critical patent/PL3424930T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL17759943T 2016-03-01 2017-02-28 Kryształ związku wykazującego aktywność hamującą JAK PL3424930T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016039315 2016-03-01
EP17759943.8A EP3424930B1 (en) 2016-03-01 2017-02-28 Crystal of compound having jak-inhibiting activity
PCT/JP2017/007594 WO2017150477A1 (ja) 2016-03-01 2017-02-28 Jak阻害作用を有する化合物の結晶

Publications (1)

Publication Number Publication Date
PL3424930T3 true PL3424930T3 (pl) 2021-05-04

Family

ID=59743962

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17759943T PL3424930T3 (pl) 2016-03-01 2017-02-28 Kryształ związku wykazującego aktywność hamującą JAK

Country Status (22)

Country Link
US (2) US10822350B2 (pl)
EP (1) EP3424930B1 (pl)
JP (1) JP6791239B2 (pl)
KR (1) KR102653231B1 (pl)
CN (1) CN108699082B (pl)
BR (1) BR112018016523B1 (pl)
CA (3) CA3206830A1 (pl)
CY (1) CY1123607T1 (pl)
DK (1) DK3424930T3 (pl)
ES (1) ES2844978T3 (pl)
HR (1) HRP20210062T1 (pl)
HU (1) HUE051615T2 (pl)
LT (1) LT3424930T (pl)
MX (1) MX385381B (pl)
PL (1) PL3424930T3 (pl)
PT (1) PT3424930T (pl)
RS (1) RS61238B1 (pl)
RU (1) RU2705721C1 (pl)
SI (1) SI3424930T1 (pl)
SM (1) SMT202000717T1 (pl)
TW (1) TWI712604B (pl)
WO (1) WO2017150477A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI712604B (zh) * 2016-03-01 2020-12-11 日商日本新藥股份有限公司 具jak抑制作用之化合物之結晶
CN120518557A (zh) * 2020-09-14 2025-08-22 欧洲化学安特卫普公司 N-杂环化合物用作硝化抑制剂
WO2025216268A1 (ja) * 2024-04-09 2025-10-16 国立研究開発法人国立循環器病研究センター 重症肺高血圧症又は膠原病の予防又は治療薬
JP7742516B1 (ja) * 2025-07-31 2025-09-19 日本新薬株式会社 好酸球性多発血管炎性肉芽腫症の処置剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3600390A1 (de) 1986-01-09 1987-07-16 Hoechst Ag Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel
US20080207613A1 (en) 2004-01-12 2008-08-28 Cytopia Research Pty Ltd Selective Kinase Inhibitors
JP2009513571A (ja) * 2005-09-30 2009-04-02 バーテックス ファーマシューティカルズ インコーポレイテッド ヤヌスキナーゼ阻害剤として有用なデアザプリン
TW201412738A (zh) 2006-01-17 2014-04-01 Vertex Pharma 適合作為傑納斯激酶(janus kinase)抑制劑之氮雜吲哚
TWI444382B (zh) 2008-03-11 2014-07-11 Incyte Corp 作為jak抑制劑之氮雜環丁烷及環丁烷衍生物
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010070060A1 (en) * 2008-12-19 2010-06-24 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
ES2461967T3 (es) 2009-12-18 2014-05-21 Pfizer Inc. Compuestos de pirrolo[2,3-d]pirimidina
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
JP2011136925A (ja) 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
WO2011086053A1 (en) 2010-01-12 2011-07-21 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
WO2012022045A1 (en) 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
AU2011302216A1 (en) 2010-09-14 2013-04-04 Exelixis, Inc. Phtalazine derivatives as JAK1 inhibitors
US8937077B2 (en) 2010-10-22 2015-01-20 Merck Sharp & Dohme Corp. Bicyclic diamines as janus kinase inhibitors
WO2012085176A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
WO2013025628A1 (en) * 2011-08-15 2013-02-21 Ligand Pharmaceuticals Incorporated Janus kinase inhibitor compounds and methods
TWI679205B (zh) 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥
TWI712604B (zh) * 2016-03-01 2020-12-11 日商日本新藥股份有限公司 具jak抑制作用之化合物之結晶

Also Published As

Publication number Publication date
JP6791239B2 (ja) 2020-11-25
TWI712604B (zh) 2020-12-11
PT3424930T (pt) 2020-12-04
CA3015464A1 (en) 2017-09-08
MX385381B (es) 2025-03-18
ES2844978T3 (es) 2021-07-23
LT3424930T (lt) 2021-01-11
WO2017150477A1 (ja) 2017-09-08
CN108699082B (zh) 2021-04-09
HUE051615T2 (hu) 2021-03-01
RU2705721C1 (ru) 2019-11-11
HRP20210062T1 (hr) 2021-03-05
EP3424930B1 (en) 2020-11-04
US11377453B2 (en) 2022-07-05
US10822350B2 (en) 2020-11-03
CA3015464C (en) 2024-04-23
TW201731855A (zh) 2017-09-16
BR112018016523B1 (pt) 2024-02-06
CY1123607T1 (el) 2022-03-24
KR20180116341A (ko) 2018-10-24
CN108699082A (zh) 2018-10-23
SMT202000717T1 (it) 2021-01-05
US20210017191A1 (en) 2021-01-21
SI3424930T1 (sl) 2021-01-29
CA3264321A1 (en) 2025-10-30
MX2018010334A (es) 2018-11-09
US20190048023A1 (en) 2019-02-14
CA3206830A1 (en) 2017-09-08
DK3424930T3 (da) 2021-01-11
BR112018016523A2 (pt) 2018-12-26
JPWO2017150477A1 (ja) 2018-12-27
EP3424930A4 (en) 2019-07-10
RS61238B1 (sr) 2021-01-29
KR102653231B1 (ko) 2024-04-01
EP3424930A1 (en) 2019-01-09

Similar Documents

Publication Publication Date Title
IL321844A (en) Menin–MLL interaction inhibitors
IL259560A (en) Inhibitors of the menin-mll interaction
PL3512850T3 (pl) Inhibitory interakcji menina-mll
IL254721B (en) 1-cyano-pyrrolidine compounds as usp30 inhibitors
IL253107A0 (en) Use of picolinamide compounds with fungicidal activity
EP3268004A4 (en) Pyrrolopyridazine inhibitors of irak4 activity
EP3268006A4 (en) Pyrrolotriazine inhibitors of irak4 activity
EP3240420A4 (en) Use of picolinamide compounds with fungicidal activity
PL3109223T3 (pl) Mieszanina do obróbki nawozów zawierających mocznik
SG11201708613SA (en) Novel crystal of uracil compound
SG11201708793SA (en) Crystals of azabicyclic compound
IL273463A (en) Crystalline forms of immunomodulators
SI3380554T2 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
IL262674A (en) crystals
SG10202101979TA (en) Crystalline forms of c21h22ci2n4o2
HUE066360T2 (hu) Eravaciklin kristályformái
PT3424930T (pt) Cristal de um composto com atividade inibidora de jak
IL253479A0 (en) Crystalline forms of efinconazole
PT3395819T (pt) Forma cristalina de derivado de aminopirano substituído
EP3212611A4 (en) Crystal forms of verapamil hydrochloride
SG10201912021VA (en) New crystal of piperazine compound
ZA201901155B (en) Salt and crystal of diaza-benzofluorane compound